CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 7 enrolled
Drug / intervention
cyclophosphamide +8 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01775475
NCT01775475Phase 2Completed

Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy With Concomitant Antiretroviral Therapy in Patients With HIV-Associated Lymphoma in Sub-Saharan Africa

AIDS Malignancy Consortium·interventional·Posted Jan 25, 2013·Updated Oct 10, 2022

In Brief

A Phase 2 clinical trial evaluating cyclophosphamide, doxorubicin hydrochloride, and 6 other interventions for AIDS-related Diffuse Large Cell Lymphoma and 8 related conditions. Completed, enrolled 7 participants across 2 sites in 2 countries.

Detailed Summary

This randomized phase II trial studies how well intravenous (IV) chemotherapy or oral chemotherapy works in treating patients with previously untreated stage III-IV human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, lomustine, etoposide, and procarbazine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells

Study Details

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 25, 2013
Enrollment StartSep 15, 2016
Primary CompletionApr 1, 2021
Study CompletionJul 15, 2021
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 13.4 years ago

Interventions

cyclophosphamidedrug

Given IV

doxorubicin hydrochloridedrug

Given IV

vincristine sulfatedrug

Given IV

prednisonedrug

Given PO

lomustinedrug

Given PO

etoposidedrug

Given PO

cyclophosphamidedrug

Given PO

procarbazine hydrochloridedrug

Given PO

laboratory biomarker analysisother

Correlative studies